Sunitinib
Therapeutic Group
Anti-neoplasticsIndication Dosage
Sunitinib is a medication used to treat certain types of cancer. It is commonly prescribed for the treatment of gastrointestinal stromal tumors (GISTs) and advanced kidney cancer (renal cell carcinoma). Sunitinib works by inhibiting the growth and spread of cancer cells in the body, thereby helping to slow down the progression of these malignancies.
Treatment Of Advanced Or Metastatic Renal Cell Carcinoma. Treatment Of Unresectable Or Metastatic Gastrointestinal Stromal Tumours (gist). Treatment Of Unresectable Or Metastatic Malignantgastro-intestinal Stromal Tumours, After Failure Ofimatinib, Treatment Of Advanced Or Metastatic Renal Cell Carcinoma:
- Adult: 50 Mg Once Daily For 4 Weeks, Followed By a week Treatment-free Period To Complete a 6-week cycle, Adjusted In Steps Of 12.5 Mg, Doses Adjusted according To Tolerability; Usual Dose 25-75 Mg Daily
Treatment Of Unresectable Or Metastatic Pancreatic Neuroendocrine Tumours:
- Adult: 37.5 Mg Once Daily Without Treatment-free Period; Adjusted In Steps Of 12.5 Mg, Doses Adjusted According To Tolerability; Maximum 50 Mg Per Day
Content
- Cap 12.5mg /25mg /50mg: Sunitinib 12.5mg /25mg /50mg.
Pregnancy
Positive Evidence Of Risk: Avoid
Stability
- Protein Kinase Inhibitor
Contra Indications
- None Known
Precautions
- None Known
Lactation
- Contraindicated. Discontinue Breast-feeding
Side Effects
- Abdominal Pain
- Alopecia
- Anorexia
- Arthralgia
- Bone-marrow Suppression
- Cough
- Gi Upset
- Dyspnea
- Epistaxis
- Fatigue
- Fistula Formation (discontinue)
- gi Perforation
- Hair& Skin Discoloration
- Hand-foot Syndrome
- Headache
- Hepatic Failure
- Hypertension
- Hyperuricaemia
- Hypothyroidism
- Increased Lacrimation
- Insomnia
- Myalgia
- Oedema
- Oral Mucositis
- Osteonecrosis Of The Jaw
- Pancreatitis
- Paraesthesia
- Peripheral Neuropathy
- Proteinuria
- Rash
- Seizures
- Thromboembolism
- Tumourlysis Syndrome
- Urine Discoloration
- Vomiting.
- Rare: Nephrotic Syndrome